The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms

****!!!!******** "While a wide range of oral sodium chlorite regi-mens have been used, the most popular are between 0.75 and 1.5 mg/kg given over 2 – 7 days in a row, followed by a rest period of 7 – 16 days, then repeat-ing (17,25,26). Importantly, it has never been shown that oral sodium chlorite can be absorbed at levels that affect human macrophage function. In rats given radiolabeled chlorite, 34% of the initial dose can be found excreted in the urine over the next 72 h (27). However, in monkeys, chlorite is neutralized in saliva within 1 min and by gastric fl uid in vivo in 5 min (28). Keuhne, one of the world ’ s experts on WF10, states that he studied oral WF10 and found that it “ can act on these mechanisms only intravenously, not orally ” (29). Furthermore, there are data that raise concerns about the safety of oral sodium chlo-rite. According to McGrath and Keuhne, sodium chlorite is converted under acidic conditions (such as those in the stomach) to chlorine dioxide, which can be poisonous (12,29). While a small, short- duration study failed to show evidence of oral chlo-rite toxicity in humans (30), Keuhne stopped his research on oral WF10 “ after two patients collapsed and one nearly died ” while taking it (29)"

"These results indicate that WF10 administration appears safe, may enhance immunologic function, and unlike other macrophage-activating cytokines does not increase HIV expression in this patient population. Further studies of WF10 in larger patient populations are warranted."

"Substances which stimulate tissue regeneration might be an attractive alternative to prevent progression of subclinical radiation injury to gross tissue failure. Since tetrachlorodecaoxygen anion complex (TCDO) has been described to have such properties "

{Includes reference to "Kahn J. A single center, phase II study evaluating the effects of WF10 (TCDO) on the kinetics of red blood cell survival, selected immunologic markers of HIV disease, macrophage activation, and the rate of change of viral kinetics. Study report for protocol WF10-96-US-003. Submitted to the US FDA, Report vol. I; 1998, 24 April."

including Tetrachlorodecaoxide (TCDO) and WF10. "This study demonstrated that WF10 at a dose of 0.5 ml/kg was associated with a sustained immunological response, i.e., sustained elevation of CD8+ T cell numbers, consistent with the proposed mechanism of action. Furthermore, a single-center, phase I/II study, was conducted in 1997 to evaluate safety and the effects of WF10" "After interaction with heme proteins, the chlorite matrix of WF10 acquires oxidizing and chlorinating properties. It has been suggested that WF10 exerts potent immunomodulatory effects most likely through generating physiologic oxidative compounds namely chloramines. Chloramines have been reported to exert cell-protective and anti-inflammatory activities. [0082] Pro-oxidative substances can also have a direct effect on transcriptional activities of the NFAT species of transcription factors."

"Treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing..."

"NP001, a pH-adjusted IV formulation of purified Sodium Chlorite, is a novel moleculethat regulates inflammation in vitro andin vivo. Within monocytes/ macrophages, chlorite is converted into taurine chloraminethat downregulates nuclear factorkB(NF-kB) expression and inhibits production of proinflammatory cytokine IL-1b. These mechanisms of downregulation trans-form inflammatory monocytes/macrophagesfrom a proinflammatory to a basal phagocyticstate." "NP001 was generally safe and well-tolerated, except for infusion site pain anddizziness. No significant slowing of decline in the primary or secondary measures was observed.However, slowing of progression was observed in the high-dose group inpatients with greaterinflammation (wide range C-reactive protein). Moreover, NP001 may have dose dependently halted symptom progression in a subset of patients. More than 2 times as many patients on high-dose NP001 (25%) did not progress during 6 months of treatment compared with thoseon placebo (11%). Most “responders”had an elevated biomarker of inflammation, interleukin-18,and were positive for lipopolysaccharide at baseline, which decreased after treatment with NP001."

"The drug substance WF10 inhibited the activation of LPS/IFNγ-stimulated humanmonocyte-derived macrophages. Among them are the diminished expression ofproinflammatory surface markers, the inhibition of the expression of the hyaluronanreceptor CD44, and the binding of hyaluronan to CD44. Further, the overall amountof sulphated proteoglycans and glycosaminoglycans was down-regulated by WF10.These in vitro experiments indicate that WF10 is able to inhibit the proinflammatory activation of macrophages. The results suggested that chlorite is the active principle inWF10 as chlorite caused principally the same changes in targets as WF10. The WF10 component chlorate inhibited only the overall sulphation level of proteoglycans and glycosaminoglycans and the binding of hyaluronan to CD44."

"The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation." "WF10, which comprises chlorite (e.g., in the form of tetrachlorodecaoxygen (TCDO)) as its active ingredient"

¿Sirve este químico para tratar el COVID-19? Contactamos al Dr. Fernando Liendo, presidente del grupo Alcos.

{Review of studies}

** {Incomplete perspective: "Chlorine Dioxide in contact with the air becomes inactivated and becomes two gases Chlorine and Oxygen, so it has no disinfectant properties, and could not serve to disinfect the air we breathe." Actually, under appropriate conditions, chlorine dioxide can be used very powerfully for disinfecting air, because dissociation is only gradual.} {Article has some other inaccuracies, along with many correct important points.}

{Contains useful info, though some statements may need verification} "CDS is chlorine dioxide without sodium chlorite content (NaClO2) in aqueous solution."

{Clinic trial of COVID-19 treatment by oral consumption of Chlorine Dioxide}

{Useful links}

The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.

{WF-10 and NP001} "... contributes to the self-limiting nature of inflammation. Sodium chlorite (NaClO2; in solution with 63 mM chlorite and pH-corrected = NP001, aka WF10) was developed to mimic this effect."

****!!!!***

***********

Discussion of Andreas Kalcker's work.

"The allylic carboxylic group resulted from aldehyde oxidation by ***sodium chlorite*** was coupled with 5-flourouracil using dicyclohexyl carbodiimide to form the target prodrug." "The results of in-vitro kinetic study indicated that the prodrug was significantly stable in both buffers with half-lives of about 36hr and 20hr respectively, and was hydrolyzed in human serum followed pseudo first order kinetics with half-life of about 8hr. Consequently, it is believed that the synthesized prodrug may be a potential candidate as oral prodrug for treatment of lung cancer, and is a first agent belongs to a new prodrug strategy, which is a coumarin-based triple mutual prodrug."

(2013). ALSUntangled No. 19: Sodium chlorite. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration: Vol. 14, No. 3, pp. 236-238.

Dr. Guery. 2,379 likes · 489 talking about this. Médico especialista en tratamiento alternativos Homeopatía, Acupuntura, Terapia del dolor, Terapia neural, Respiraciones para bajar de peso,...

La doctora Callisperis tenía una enfermedad en la boca que le impedía hasta el habla. Ningún médico conseguía dar con su enfermedad, ni en Bolivia, ni en Brasil ni en Estados Unidos. Probó el dióxido de cloro... y hasta hoy. “El dióxido de cloro es una sustancia que provoca una oxigenación celular a nivel mitocondrial”, dice, refiriéndose a cómo actúa

IV amt is given w/non-acidic, 99.999% pure chlorine dioxide. "CDS (for drinking) is reaction of sodium chlorite and 4% hydrochloric acid." "LD50 is 292 mg/kg for 14 days. We use 10 mg or mL in a liter of water. The difference is overwhelming."

President of the Senate, Eva Copa, appointed 4 people from COBOSOL (Bolivian organization) committee: Dr Helmunt Lema, Ms. Karla Rebollo, Wofgang Vargas & Guery Cordero.

[Chlorine dioxide (Clidox-s) is a broad spectrum, oxidizing disinfectant which is relatively non-irritating to skin and ocular tissues. The recommended chlorine dioxide solution used in this article was prepared as a 1:5:1 (base: tap water: activator) - the 1:18:1 strength was not recommended. Chlorine dioxide alone failed to control bacteria in vivo" noted at http://labsg.org/ct372.htm] "After use ofthe prophylactic regimen B for 1 year, these macaques did nothave any adverse clinical signs or pathologic alterations thatmight have been attributed to the use of chlorine dioxide. " "Chlorine dioxide may serve as a useful adjunct to antibioticsfor prophylactic maintenance of cephalic recording cylinders; however, it was beyond the scope of this study to determinewhether the corrosive nature of this agent might contraindi-cate its use on a long-term basis because of adverse effects ontissues or implant materials. We did find chlorine dioxide to behighly effective in resolving localized mycotic growth withincranial cylinder chambers in the 4 subject macaques. Decon-tamination was achieved after 1 or 2 applications and its usemay preclude the necessity of using systemically administeredantimycotic agents, making it potentially useful for short-termtreatment of mycotic infections."

Effectiveness in patients treated in different stages of COVID-19.